1 Lyman GH, Marc Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood advances 2021;5:927–74.
2 Wuillemin WA, Spirk D, Jeanneret-Gris C, Meier B. Commentaires d’experts suisses sur les lignes directrices de l’ASH et de l’ESC relatives aux maladies thromboemboliques. Forum Med Suisse. 2021:21(33–34):563–5.
3 Lyman GH, Culakova E, Poniewierski MS, Kuderer NM. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164(suppl 1):S112–S118.
4 Graf L, Beer JH, Hayoz D. Prophylaxie des thromboembolies veineuses chez les patients médicaux hospitalisés et ambulatoires. Forum Med Suisse. 2021:21(45–46):768–71.
5 Tsakiris DA, Siebenrock KA, Spahn DR. Prophylaxie de la thromboembolie veineuse chez les patients hospitalisés en chirurgie. Forum Med Suisse. 2021;21(37–38):628–31.
6 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902–7.
7 Agnelli G. Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer. New Engl J Med. 2019;380:781–3.
8 Storrar NPF, Mathur A, Johnson PRE, Roddie PH. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol 2019;185:142–4.
9 Machado M, Ruosch-Girsberger S, Hegglin A, Wuillemin WA. Antikoagulation bei venöser Thromboembolie: wie lange und welche Dosierung? Praxis 2020;109:270–6.